Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abiogen Pharma SRL
Original Assignee
Abiogen Pharma S.R.L.
Giulio Barelli
Massimo De Regis
Abiogen Pharma S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IT95MI002337Aexternal-prioritypatent/IT1276130B1/en
Application filed by Abiogen Pharma S.R.L., Giulio Barelli, Massimo De Regis, Abiogen Pharma S.P.A.filedCriticalAbiogen Pharma S.R.L.
Publication of CA2237571A1publicationCriticalpatent/CA2237571A1/en
Application grantedgrantedCritical
Publication of CA2237571CpublicationCriticalpatent/CA2237571C/en
A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
A61K31/00—Medicinal preparations containing organic active ingredients
A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
Abstract
A combination of glibenclamide and metformin such that, when administered in the form of pharmaceutical composition in the treatment of diabetes mellitus of type II, the ratio between the two active principles allows to obtain an optimum therapeutical effect at any time of the progression of the disease, avoiding to make use of the insulin therapy in the most severe cases.
CA002237571A1995-11-141996-11-07A glibenclamide-metformin combination for the treatment of diabetes mellitus of type ii
Expired - Fee RelatedCA2237571C
(en)